{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-091357","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.896981+00:00","generated_at":"2026-05-23T08:51:59.932514+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ResMed Q3 FY2025: revenue $1.29B (+8%), GAAP EPS $2.48 (+22%), non-GAAP EPS $2.37 (+11%)","bullets":["Revenue of $1.29B (+8% YoY; +9% constant currency); GAAP diluted EPS $2.48 vs $2.04 (+22%).","Gross margin improved 140 bps to 59.3%; non-GAAP gross margin 59.9%.","Operating income up 14% to $426.3M; non-GAAP operating income up 13% to $444.6M.","Operating cash flow of $579M in the quarter.","Quarterly dividend of $0.53/share declared; payable June 12, 2025 to holders of record May 8, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-091357","json":"https://secwatch.observer/filing/0001193125-25-091357.json","markdown":"https://secwatch.observer/filing/0001193125-25-091357.md","text":"https://secwatch.observer/filing/0001193125-25-091357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312525091357/0001193125-25-091357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312525091357/d830100d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:51:59.932514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}